Home | Welcome to Contract Pharma   
Last Updated Wednesday, October 1 2014
Print

Onyx Invests in Continuous Flow Technology



Published June 23, 2014
Onyx Scientific is investing in continuous flow manufacturing to offer clients alternatives during product research and development programs and to help overcome time-consuming and costly processes of API batch manufacturing. Onyx is also expanding its GMP capability for its API manufacturing services.
 
Denise Bowser, commercial director at Onyx Scientific, said, “The move to continuous flow manufacturing has been seen by a handful of companies in the sector to date so we feel that we are very much at the forefront of technological advances when it comes to the development and production of API.For us, it makes better use of our space, gives us a quicker output and provides greater flexibility in the manufacturing of compounds as well as delivering considerable cost savings, which we can pass onto clients.”
 
Ms. Bowser added, “Over the last year or so, we’ve felt a surge in demand for GMP manufacturing at our site in Sunderland so have moved to increase capacity by investing in additional vessels to satisfy market demand.The integration of pre- formulation development and GMP manufacturing has really benefited many clients over the last two years and this is a trend that we expect to continue in the future as clients look for smarter ways to develop compounds.”


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On